Tees River, a hedge fund, led a funding round in Ionetix, a cyclotron technology innovator and isotope manufacturer for diagnostic and therapeutic applications, with participation from Eli Lilly and Company, a pharmaceutical company. Financial terms were not disclosed. “Our experience with other critical resources enabled us to understand the significant supply constraints facing the growing radiotherapeutic space. We are pleased to further support Ionetix as they scale supply of cyclotron-produced alpha-emitters," Sean Benson, Tees River Founder and Chief Investment Officer.